Nabriva Therapeutics AG – ADR(NASDAQ:NBRV) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $899.00K. Analysts estimated a revenue of $990.00K. Earnings per share were $-9.03. Analysts had estimated an EPS of $-6.25.
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin a Phase Two plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) and BC-7013 a Phase One topical pleuromutilin treatment for Gram-positive infections including uncomplicated skin and skin structure infections (uSSSSIs). In addition the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and in Discovery Phase development of extended-spectrum pleuromutilins (ESPs) a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH and receives investment from HBM Healthcare Investments Novartis Venture Fund Omega Funds OrbiMed Healthcare Fund Management Phase4 Partners Vivo Capital and the Wellcome Trust.